Nuvilex (NASDAQ:PMCB – Get Free Report)‘s stock had its “sell (d)” rating reiterated by equities researchers at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.
Nuvilex Stock Performance
Nuvilex stock opened at $0.98 on Friday. The firm’s fifty day moving average price is $0.99 and its 200-day moving average price is $1.04. The stock has a market cap of $6.64 million, a P/E ratio of -1.81 and a beta of -0.05. Nuvilex has a fifty-two week low of $0.80 and a fifty-two week high of $2.42.
Nuvilex (NASDAQ:PMCB – Get Free Report) last posted its quarterly earnings data on Monday, September 15th. The company reported ($0.09) earnings per share for the quarter.
Nuvilex Company Profile
PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.
Featured Stories
- Five stocks we like better than Nuvilex
- Which Wall Street Analysts are the Most Accurate?
- Tractor Supply Stock Looks Like a Buy-and-Hold Winner
- Industrial Products Stocks Investing
- 3 Stocks Well Below 52-Week Highs Poised for a Q4 Rebound
- Are Penny Stocks a Good Fit for Your Portfolio?
- Big Banks Are Setting the Tone as Earnings Season Kicks Off
Receive News & Ratings for Nuvilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvilex and related companies with MarketBeat.com's FREE daily email newsletter.
